The Asia Pacific Genetic Toxicology Testing Market would witness market growth of 14.2% CAGR during the forecast period (2022-2028).
Research has found that a variety of anticancer medications, including topoisomerase II inhibitors, alkylating agents, and thiopurines, can kill cancer cells and also cause sub-lethal mutations in healthy somatic cells, which may result in secondary cancers linked to the treatment. A study revealed that patients suffering from chronic lymphocytic leukemia who underwent cyclophosphamide, frontline fludarabine, and rituximab therapy had higher rates of AML and MDS and 2.38 times the risk of second malignancies compared to the general population.
Consequently, it is important to evaluate the genotoxicity of chemotherapeutic medications. There are currently many in vitro and in vivo genotoxic diagnostics, including the PIG-A assay, for tracking the genotoxicity in individuals following chemotherapy. Since it is simple to identify the mutagens in somatic cells using short-term experiments, the emphasis of genotoxicology has shifted significantly to somatic cells from germ cells and their relationship to cancer.
It was also challenging to identify human cell mutagens due to a lack of sensitive and practical innovative techniques for identifying genotoxic mutagenic consequences in germ cells. While somatic cell mutations need to accumulate over time before becoming malignant, germ cell mutations have the potential to cause a variety of disorders, prompting an increasing number of research to explore the occurrence and significance of such mutagens.
The revolution in genomics and precision medicine is well underway in the Asia Pacific region. Large worldwide collaborative efforts including the Global Alliance for Genomics and Health, International Human Epigenome Consortium, and the International Cancer Genome Consortium all involve participation from Asian nations. Using the large amounts of data that were taken from their populations, they have proactively set up public biobanks. The Hong Kong Genome Institute was formed by the Hong Kong government in 2020 to carry out large-scale genome sequencing.
The China market dominated the Asia Pacific Genetic Toxicology Testing Market by Country in 2021; thereby, achieving a market value of $192.2 million by 2028. The Japan market is registering a CAGR of 13.5% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 14.9% during (2022 - 2028).
Based on Product, the market is segmented into Services, Reagents & Consumables and Assays. Based on Type, the market is segmented into In Vitro and In Vivo. Based on Application, the market is segmented into Pharmaceutical & Biotechnology, Food Industry, Cosmetics Industry and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Genetic Toxicology Testing Market is Projected to reach USD 2.4 Billion by 2028, at a CAGR of 13.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings, Eurofins Scientific Group, Jubilant Pharmova Limited., Syngene International Limited, Gentronix Ltd., Inotiv Inc., Creative Bioarray and MB Research Laboratories.
By Product
By Type
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
